全文获取类型
收费全文 | 6401篇 |
免费 | 350篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 97篇 |
妇产科学 | 42篇 |
基础医学 | 798篇 |
口腔科学 | 108篇 |
临床医学 | 455篇 |
内科学 | 1460篇 |
皮肤病学 | 179篇 |
神经病学 | 422篇 |
特种医学 | 283篇 |
外科学 | 1106篇 |
综合类 | 15篇 |
预防医学 | 213篇 |
眼科学 | 266篇 |
药学 | 434篇 |
中国医学 | 21篇 |
肿瘤学 | 844篇 |
出版年
2023年 | 39篇 |
2022年 | 67篇 |
2021年 | 128篇 |
2020年 | 60篇 |
2019年 | 110篇 |
2018年 | 133篇 |
2017年 | 98篇 |
2016年 | 122篇 |
2015年 | 152篇 |
2014年 | 201篇 |
2013年 | 234篇 |
2012年 | 382篇 |
2011年 | 393篇 |
2010年 | 239篇 |
2009年 | 200篇 |
2008年 | 368篇 |
2007年 | 412篇 |
2006年 | 374篇 |
2005年 | 359篇 |
2004年 | 309篇 |
2003年 | 288篇 |
2002年 | 266篇 |
2001年 | 167篇 |
2000年 | 171篇 |
1999年 | 143篇 |
1998年 | 80篇 |
1997年 | 58篇 |
1996年 | 52篇 |
1995年 | 41篇 |
1994年 | 40篇 |
1993年 | 37篇 |
1992年 | 132篇 |
1991年 | 107篇 |
1990年 | 86篇 |
1989年 | 77篇 |
1988年 | 100篇 |
1987年 | 72篇 |
1986年 | 57篇 |
1985年 | 52篇 |
1984年 | 39篇 |
1983年 | 39篇 |
1982年 | 19篇 |
1979年 | 31篇 |
1977年 | 18篇 |
1975年 | 22篇 |
1973年 | 18篇 |
1972年 | 20篇 |
1970年 | 18篇 |
1969年 | 17篇 |
1968年 | 20篇 |
排序方式: 共有6784条查询结果,搜索用时 15 毫秒
121.
122.
Miki Sato MD Wataru Yamadera MD PhD Masato Matsushima MD PhD Hiroshi Itoh MD PhD Kazuhiko Nakayama MD PhD 《Psychiatry and clinical neurosciences》2010,64(2):187-195
Aim: Twenty patients (14 of them women) suffering from psychophysiological insomnia (PPI) were enrolled for cognitive behavior therapy (CBT). The mean age of the patients was 56.9 years, and the mean duration of insomnia morbidity was 8.9 years. Each received individual combined CBT treatments consisting of stimulus control, sleep reduction, cognitive therapy and sleep hygiene education over a period of 1 month. Methods: Just before the CBT and after its completion, sleep measurements were conducted that involved (i) sleep logs, Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS), and the Pittsburgh Sleep Quality Index (PSQI); (ii) actigraphy measurement; (iii) dissociation between subjective and objective evaluation of sleep calculated from sleep logs and actigraphy results; and (iv) correlation between DBAS and the aforementioned sleep parameters. Because the intention was to focus on patients' incorrect cognition about sleep, the definition ‘changes in dissociation between the sleep log and actigraphically measured sleep’ was used as the primary outcome and ‘changes in DBAS score’ as the secondary outcome. Results: After the CBT the following was found: (i) underestimation by PPI patients of the objective evaluation of sleep; (ii) a decrease in the dissociation between the subjective and objective evaluation of sleep; (iii) improvement of the DBAS; and (iv) improvement of sleep logs and actigraphy measurements. Moreover, there was a correlation between the improvement of PSQI, sleep logs and DBAS. Conclusion: CBT for insomnia is able to redress incorrect cognition about sleep, leading to improvement of the disorder. 相似文献
123.
124.
Katsuhisa Omagari Shun-ichi Morikawa Seiko Nagaoka Yukiko Sadakane Miki Sato Mizuho Hamasaki Shigeko Kato Jun-ichi Masuda Masayuki Osabe Takehiko Kadota Keisuke Sera 《Journal of Clinical Biochemistry and Nutrition》2009,45(1):56-67
Fatty liver is commonly associated with alcohol or metabolic syndrome. We aimed to examine the longitudinal aspects of fatty liver, and clarify the independent predictors for the development or regression of fatty liver. In the present study, the clinical features of 1578 Japanese adults (1208 men and 370 women; 35 to 69 years of age) who visited our center both in 2000 and 2007–2008 were recorded and compared, including liver status diagnosed by ultrasonography. Of the 1578 participants, 217 (13.8%) showed fatty liver development, and 74 (4.7%) showed fatty liver regression. Logistic regression analysis revealed that body mass index and percentage body fat were strongly associated with the development or regression of fatty liver. Metabolic syndrome-related disorders such as serum levels of total cholesterol, triglyceride, uric acid, and fasting blood glucose were also associated with clinical course to some degree. However, the history of alcohol intake, the presence of metabolic syndrome, blood pressure, and habitual physical exercise were not independent predictors for the development or regression of fatty liver. Our present data suggest that control of body weight in men and the percentage body fat in women are particularly important for the prevention or treatment of fatty liver. 相似文献
125.
Nakamura S Nakamura R Shibata K Kobayashi M Sahara N Shigeno K Shinjo K Naito K Ohnishi K Kasahara N Iwaki Y 《European journal of haematology》2004,73(4):285-294
Adeno-associated virus (AAV) vector system has several useful advantages with regard to in vitro and in vivo gene transfer. However, their usages have been limited by cumbersome and labor-intensive vector production in the traditional method. To overcome limitations in AAV production, in this report, we explored the possibility of generating AAV packaging cell line, 293T R/C.VA.E2A.E4. cells, by using lentivirus-mediated transduction of Rep/Cap gene of AAV-2, VA RNA, E2A, and E4 genes of Ad5 into 293T cells. In packaging cell lines, it is important that supply of the AAV vector can be stably performed for long time. We showed that the 293T R/C.VA.E2A.E4. cells have stably maintained the transduced components after more than 10 passages and yielded high-titer AAV vectors, and the titer of AAV vectors did not decline even if culture of the packaging cells was continued for long time. The Rep/Cap and E4 gene products caused no remarkable cytotoxicity. The 293T R/C.VA.E2A.E4. cells might be able to tolerate the Rep/Cap and E4 gene products, or have less copy numbers of the Rep/Cap and E4 genes than the traditional method. Moreover, we showed that the AAV vectors derived from 293T R/C.VA.E2A.E4. cells infected the primary human CD34+ haematopoietic progenitor cells with high efficiency (50-70%). In the 293T R/C.VA.E2A.E4. cells, the AAV vectors can be generated by the transfection of one AAV vector plasmid, and large-scale AAV production can be easily achieved. It is important that cumbersome, variable, and costly transfection is avoided. 相似文献
126.
Fumiki?Yoshihara Miki?Imazu Toshimitsu?Hamasaki Toshihisa?Anzai Satoshi?Yasuda Shin?Ito Haruko?Yamamoto Kazuhiko?Hashimura Yoshio?Yasumura Kiyoshi?Mori Masataka?Watanabe Masanori?Asakura Masafumi?Kitakaze 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2018,32(2):183-190
Background and Aims
Sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, which are anti-diabetic drugs, reportedly decrease the incidence of cardiovascular events in high-risk patients with cardiovascular diseases, and thus chronic heart failure (CHF). SGLT-2 inhibitors also decrease albuminuria in patients with type 2 diabetes mellitus (T2D). Since albuminuria is a biomarker of not only chronic kidney disease but also cardiovascular events, we hypothesized that, among T2D patients with CHF, SGLT-2 inhibitors will decrease the extent of albuminuria and also improve CHF concomitantly.Methods
DAPPER (UMIN000025102) is a multicenter, randomized, open-labeled, parallel-group, standard treatment-controlled study, which is designed to evaluate whether dapagliflozin, one of the SGLT-2 inhibitors, decreases albuminuria in T2D patients with CHF and exerts cardioprotective effects on the failing heart. The patients are randomized to either of the dapagliflozin (5 or 10 mg, once daily orally) or control group (administration of anti-diabetic drugs administered other than SGLT 2 inhibitors). The estimated number of patients that need to be enrolled is 446 in total (223 in each group). The primary objective is the changes in the urinary albumin-to-creatinine ratio from the baseline after 2-year treatment. The key secondary objectives are (1) the safety of dapagliflozin and (2) the cardiovascular and renal efficacies of dapagliflozin.Conclusion and Perspectives
DAPPER study investigates whether dapagliflozin decreases albuminuria and exerts beneficial effects on the failing heart in T2D patients. (UMIN000025102).127.
To obtain insight into the role of the mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channel in ischemic preconditioning (PC), we aimed to clarify the mitoK(ATP) channel-dependent phase of PC in two PC protocols with different intervals between PC ischemia and an index ischemia. The possible contribution of mitoK(ATP) channel opening to protein kinase C activation in PC was also examined by Western blotting. Myocardial infarction was induced by 30-min coronary occlusion/2-h reperfusion in rat hearts in situ, and infarct size was expressed as a percentage of the area at risk (% IS/AR). PC was performed with 2 episodes of 5-min ischemia, and each heart was subjected to 30-min ischemia either 5 min or 20 min after PC. At 5 min after PC, both PKC-delta and -epsilon were translocated and the myocardium was protected against infarction (% IS/AR = 28.3 +/- 2.7 % vs. 72.7 +/- 2.2 in controls p < 0.05). Pretreatment with a selective mitoK(ATP) channel blocker, 5-hydroxydecanoate (5-HD, 10 mg/kg), abolished the cardioprotection but not PKC translocation by PC. At 20 min after PC, PKC translocation remained at the same level as that 5 min after PC, but the anti-infarct tolerance was attenuated (%IS/AR = 43.5 +/- 4.7 %). Injection of 5-HD after PC did not affect anti-infarct tolerance at 5 min after PC but abolished the protection at 20 min after PC without any effects on PKC. These results suggest that the mitoK(ATP) channel plays a role in triggering of PC in a PKC-independent manner and that the role of the mitoK(ATP) channel as a mediator of protection is detectable after, but not before, the PC effect starts to decay without a change in the level of PKC translocation in the rat heart. 相似文献
128.
Altered relationship between body fat and plasma adiponectin in end-stage renal disease 总被引:2,自引:0,他引:2
Shoji T Shinohara K Hatsuda S Kimoto E Fukumoto S Emoto M Tahara H Koyama H Ishimura E Miki T Tabata T Nishizawa Y 《Metabolism: clinical and experimental》2005,54(3):330-334
Patients with end-stage renal disease (ESRD) show an inverse association between body mass index and risk of death from cardiovascular disease. Paradoxical epidemiology may suggest some beneficial effects of body fat in ESRD. Because an antiatherogenic adipocytokine adiponectin is increased in uremic plasma, we tested a hypothesis that, in ESRD, plasma adipocytokine profile may be less atherogenic or that the relationship between body fat and adipocytokines may be altered. The subjects were 103 patients with ESRD undergoing hemodialysis and 166 healthy subjects comparable in age and sex. We measured body fat mass by dual-energy x-ray absorptiometry and plasma levels of adiponectin and leptin by enzyme-linked immunosorbent assay. The ESRD group showed a significant increase in plasma adiponectin, leptin, and adiponectin/leptin ratio than the healthy subjects. Although sex and fat mass were significant factors correlating with plasma adiponectin level in the healthy group, none of these were significantly associated with plasma adiponectin in the patients with ESRD. In contrast, leptin showed significant relationships with sex and fat mass regardless of the presence of ESRD. Plasma adiponectin correlated negatively with plasma triglycerides and positively with high-density lipoprotein cholesterol in both healthy and ESRD groups, suggesting that uremic adiponectin retains its actions in favor of its antiatherogenicity. Thus, plasma adipocytokine profile was altered in ESRD, and the effects of body fat and sex on adiponectin were less significant in the patients with ESRD. 相似文献
129.
130.